Percheron Therapeutics Limited · ASX:PER
Percheron Therapeutics — Shareholder Meeting (November 2024)
22 slides from Percheron Therapeutics's shareholder meeting presentation, Nov 21, 2024
Slide 1: AGM Presentation ASX Announcement
ASX Announcement • AGM PRESENTATION Melbourne, Australia – 21 November 2024: In advance of this morning’s Annual General Meeting of shareholders to be held at 10:00am, and in accordance with ASX Listing Rule 3.13.3, Percheron Therapeutics Limited (ASX: PER or ‘the Company’) is pleased to provide a c
Slide 2: 2024 – A Transformative Year
For personal use only 2024 – A Transformative Year Presentation to Annual General Meeting of Shareholders Dr James Garner Chief Executive Officer Melbourne, VIC 21 November 2024 www.PercheronTx.com ASX: PER | US OTC: ATHJY
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements do not relate strictly to historical or current facts and may be accompanied by words such as ‘c
Slide 4: Agenda
Agenda For personal use only • 2024 in Review • December Data Read-Out • Looking Ahead to 2025 2
Slide 5: Key Highlights 2024
Key Highlights 2024 Full recruitment to international phase IIb randomised, placebo-controlled clinical trial of avicursen in DMD, with initial six- For personal use only month data expected in December 2024 Full completion of nine-month primate toxicology study, laying the path to regulatory discus
Slide 6: The year has been characterised by extensive engagement with clinicians, investors, and patient advocacy
The year has been characterised by extensive engagement with clinicians, investors, and patient advocacy For personal use only 4
Slide 7: The company's successes have been reflected in market performance
The company’s successes have been reflected in market performance Year-to-Date Return Exceeds All Comparable Indices Enterprise Value has More Than Doubled in FY2024 For personal use only Annualised Return in Share Price (%) Value (AU$ million) 1 Nov 23 – 31 Oct 24 50% 90 Market Capitalisation 42% 8
Slide 8: Capital raise in October 2024 leaves the company funded into CY2026
Percheron’s capital raise in October 2024 leaves the company funded into CY2026 At average historical spend, funds on hand provide Companies with good access to capital have For personal use only cash into CY2026 outperformed in FY2024 Operating Cashflows Total Shareholder Return (AU$ ,000) FY2024 2
Slide 9: 2024 has been an active year in the DMD field
2024 has been an active year in the DMD field, with a number of developmental therapies seeing important milestones For personal use only January 2024 April 2024 May 2024 June 2024 September 2024 October 2024 Solid Biosciences Long-term NS Pharma’s Viltepso First generic Capricor Therapeutics Capric
Slide 10: Broader biotech environment remains challenging, with green shoots of recovery
The broader environment remains challenging for biotech, but there are green shoots of recovery among more substantial companies Total number of biotech companies …but attrition is worst in companies …and late-stage companies are being For personal use only is declining… with negative enterprise val
Slide 11: Agenda
Agenda For personal use only • 2024 in Review • December Data Read-Out • Looking Ahead to 2025 9
Slide 12: Phase IIb study of avicursen in DMD will provide initial six-month read-out in December 2024
The ongoing phase IIb study of avicursen (ATL1102) in DMD will provide an initial six- month read-out in December 2024 For personal use only Patient Population Blinded Treatment Open-Label Treatment Follow-Up Period Placebo Period Period • Genetically (n≈16) confirmed DMD • 6 months duration • 6 mon
Slide 13: The December 2024 read-out will be the first read-out, with further data in CY2025
The December 2024 read-out will be the first read-out from the study, but further data will follow over the course of CY2025 • December read-out will be ‘top-line’ data: a summary of efficacy, safety, and For personal use only patient demographics • Detailed information, including secondary outcomes
Slide 14: Key questions for avicursen in DMD (1/3)
The 6-month read-out will begin to answer a number of key questions for avicursen in DMD (1/3) 1 2 The study aims to detect a difference in PUL2.0 score between For personal use only Is the difference statistically significant? avicursen and placebo PUL2.0 ILLUSTRATIVE ONLY PUL2.0 ILLUSTRATIVE ONLY
Slide 15: Key questions for avicursen in DMD (2/3)
The 6-month read-out will begin to answer a number of key questions for avicursen in DMD (2/3) 3 4 Does the placebo group resemble placebo groups in comparable For personal use only What is the trajectory of avicursen-treated patients? studies, and the historical control in the phase IIa study? PUL2
Slide 16: Key questions for avicursen in DMD (3/3)
The 6-month read-out will begin to answer a number of key questions for avicursen in DMD (3/3) 5 6 How does the safety profile of avicursen appear, For personal use only How does the drug perform in the secondary endpoints? in the context of approved DMD therapies? ILLUSTRATIVE ONLY Safety Considera
Slide 17: Agenda
Agenda For personal use only • 2024 in Review • December Data Read-Out • Looking Ahead to 2025 15
Slide 18: Six-month data will define the likely path to market for avicursen
Six-month data from the ongoing phase IIb trial of avicursen will define the likely path to market for the drug For personal use only Pediatric Priority Review Voucher (pPRV) Discussion with FDA and other regulatory • PRV system designed to incentivise private sector to Positive Data agencies regard
Slide 19: Broad outreach program to identify and cultivate potential future partners
The company has initiated a broad outreach program to identify and cultivate potential future partners for avicursen Illustrative Composition of Typical Pharma Partnering Benchmarks for Phase II Rare Disease Partnering Transactions For personal use only Transactions (2016 – 2023) (n=47) • A share of
Slide 20: We have five key objectives for FY25
We have five key objectives for FY25 For personal use only Complete phase IIb clinical trial of avicursen in DMD 1 - Key data readouts in December 2024 (6-month data), mid-CY2025 (12-month data), and 2H-CY2025 (16-month data) Lift clinical hold with FDA and define a path-to-market for avicursen in D
Slide 21: Near-term news flow with potential value-driving catalysts over next 18 months
Percheron is rich in near-term news flow, with the potential for multiple value-driving catalysts over the next 18 months ✓ - completed CY2024 For personal use only Full recruitment to international phase IIb study of avicursen in Duchenne muscular dystrophy 1H CY2024 ✓ Operational completion of 9-m
Slide 22: For personal use only
For personal use only info@PercheronTx.com www.PercheronTx.com
Percheron Therapeutics — Shareholder Meeting (November 2024) on 6ix